MPI and OV announces registration of trademark for DRP
Hoersholm, Denmark – November 1st 2017 – Oncology Venture Sweden AB:s (OV:ST) and Medical Prognosis Institute A/S (MPI.ST) today informed that the United States Patent & Trademark Office (USTPO) has allowed and registered its primary trademark, DRP®, used in connection with the Company’s core predictive biomarker platform and services.
The DRP® biomarker platform uses tumor mRNA and proprietary analytics to develop tumor-derived genetic signatures, which are used to identify which cancer patients are likely to respond to a given anti-cancer drug. This proprietary technology has been validated in over 37 clinical studies to date.
Drug-specific DRP® biomarkers are being used as companion diagnostics (CDx) for Phase 2 anti-cancer drugs in development at Oncology Venture Sweden AB (OV.ST) and U.S.-based 2X Oncology. The CDx is used to identify and select likely responder patients for inclusion in relevant clinical trials. This precision medicine approach is expected to enable personalized oncology treatments for all cancer types including breast, ovarian, prostate and pancreatic cancers and multiple myeloma which are the initial foci for the use in drug development.
About MPI’s Drug Response Predictor - DRP®
MPI’s DRP® is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP® has been tested in 37 trials, where 29 trials showed that drug-specific DRP® Biomarkers could predict which patients responded well to the treatment. The DRP® platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP® method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anti-cancer drug. In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP® builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP® is a Big Data tool based on messenger RNA.
The DRP® platform can be used in all cancer types, and has been patented for more than 60 anti-cancer drugs in the US.
For further information, please contact:
|Ulla Hald Buhl, COO and Chief IR & CommunicationsMobile: +45 2170 firstname.lastname@example.org||or||Peter Buhl Jensen, CEOMobile: +45 21 60 89 22E-mail: email@example.com|
About Oncology Venture Sweden AB
Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has an exclusive license to use the Drug Response Predictor (DRP®) technology in order to significantly increase the probability of success in clinical trials. DRP®F has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors’ genes are screened first with DRP® and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.
The current product portfolio: LiPlaCis® for breast cancer in collaboration with Cadila Pharmaceuticals; Irofulven developed from a fungus for prostate cancer; and APO010 – an immuno-oncology product for multiple myeloma.
Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US-based company focusing on precision medicine for women’s cancers with a pipeline of three promising Phase 2 product candidates, and Danish OV-SPV 2 which will test and potentially develop the Novartis small molecule kinase inhibitor. Oncology Venture currently owns 92% of 2X Oncology Inc. and 40% of OV-SPV2 ApS.